Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity

D Nowis1, M Legat, T Grzela

  • 1Department of Immunology, Center of Biostructure Research, The Medical University of Warsaw, Warsaw, Poland.

Oncogene
|February 8, 2006
PubMed

Insights

Photodynamic therapy (PDT) shows promise against tumors. Our study reveals that heme oxygenase-1 (HO-1) protects tumor cells from PDT, suggesting HO-1 inhibitors could enhance treatment effectiveness.

Area of Science:

  • Oncology
  • Biochemistry
  • Photomedicine

Background:

  • Photodynamic therapy (PDT) is an approved antitumor treatment.
  • PDT utilizes reactive oxygen species to damage tumor cells and vasculature.
  • Tumor cells exhibit protective responses against PDT, necessitating further research into these mechanisms.

Purpose of the Study:

  • To identify stress-related genes induced by Photofrin-mediated PDT.
  • To investigate the role of heme oxygenase-1 (HO-1) in cellular resistance to PDT.
  • To explore the potential of HO-1 inhibition as a strategy to enhance PDT efficacy.

Main Methods:

  • DNA microarray analysis of colon adenocarcinoma C-26 cells post-PDT.
  • Investigating the effect of HO-1 induction (hemin, transfection) on PDT cytotoxicity.
  • Assessing the impact of an HO-1 inhibitor (zinc protoporphyrin IX) and iron chelator (desferrioxamine) on PDT efficacy.

Main Results:

  • Heme oxygenase-1 (HO-1) was significantly induced by Photofrin-mediated PDT.
  • HO-1 induction conferred resistance to PDT-mediated cytotoxicity in tumor cells.
  • Inhibition of HO-1 or iron chelation markedly enhanced PDT-induced tumor cell death.

Conclusions:

  • HO-1 plays a critical role in the protective response against PDT-induced phototoxicity.
  • Inhibiting HO-1 represents a viable strategy to potentiate the antitumor effectiveness of PDT.
  • Targeting HO-1 could lead to improved combination therapies for cancer treatment.

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...